Tempus AI surged 13% in morning trading on Wednesday, lifting its stock to a session high of $59.04 after the company reported its first quarterly net profit and raised full-year revenue guidance.
The Chicago-based AI precision medicine company posted Q2 2026 net income of $5.6 million, a sharp turnaround from a $42.8 million loss in the same period a year earlier. Revenue grew 22% year-over-year to $382.5 million, while management increased its full-year 2026 revenue guidance to a range of $1.595 billion to $1.605 billion. Adjusted EBITDA was projected at approximately $65 million.
The gains followed the release of a study validating Tempus AI’s PRISM2 AI platform, published in Nature Medicine on August 4. The company also announced a strategic partnership with CellCarta on August 6, under which Tempus was added as a commercial laboratory partner within CellCarta’s oncology companion diagnostics network.
Tempus AI’s stock climbed to $55.79, well above its 52-week low of $40.77. Short interest remained elevated, with more than 26% of the float sold short. The broader market showed modest gains, with the S&P 500 up 0.4% and the Nasdaq up 0.1% on the day of the report.
